A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ROQUEFORT THERAPEUTICS PLC ORD operates in the Biotechnology industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | 0 | - |
| Net Income | -1.2M | -1.2M | -2.2M | -2.0M | -1.4M |
| EPS | $0.00 | - | - | - | - |
| Free Cash Flow | -1.0M | -1.0M | -2.2M | -1.9M | -140K |
| ROIC | -20.3% | -18.7% | -29.6% | -31.4% | -26.3% |
| Gross Margin | - | - | - | - | - |
| Debt/Equity | 0.00 | - | - | - | - |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | -1.5M | -1.5M | -2.4M | -2.0M | -1.4M |
| Operating Margin | 0.0% | - | - | - | - |
| ROE | -19.9% | -19.0% | -27.7% | -27.5% | -25.3% |
| Shares Outstanding | 0M | - | - | - | - |
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | N/A | 0 | N/A | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | -394K | -774K | -196K | -196K |
| SG&A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -1.4M | -2.0M | -2.4M | -1.5M | -1.5M |
| Op. Margin | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -1.4M | -2.0M | -2.2M | -1.2M | -1.2M |
| Net Margin | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||
| ROIC | -26.3% | -31.4% | -29.6% | -18.7% | -20.3% |
| ROE | -25.3% | -27.5% | -27.7% | -19.0% | -19.9% |
| ROA | N/A | -20.8% | -25.4% | -16.6% | -16.9% |
| Cash Flow | |||||
| Op. Cash Flow | -140K | -1.9M | -2.2M | -1.0M | -1.0M |
| Free Cash Flow | -140K | -1.9M | -2.2M | -1.0M | -1.0M |
| Owner Earnings | -669K | -2.0M | -2.2M | -1.0M | -1.0M |
| CapEx | 0 | 0 | 67K | 0 | 0 |
| Maint. CapEx | 0 | 0 | 5K | 7K | 7K |
| Growth CapEx | N/A | N/A | 63K | N/A | 0 |
| D&A | 0 | 0 | 5K | 7K | 7K |
| CapEx/OCF | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 529K | 10K | 13K | 27K | 27K |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||
| Net Debt | N/A | N/A | N/A | N/A | -431K |
| Cash & Equiv. | 1.2M | 2.9M | 671K | 431K | 431K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | N/A | N/A | N/A | N/A | 0.00 |
| Interest Coverage | N/A | N/A | -33314.4 | -26.1 | -26.1 |
| Equity | 5.6M | 8.9M | 6.9M | 6.3M | 6.3M |
| Total Assets | N/A | 9.6M | 7.6M | 7.4M | 7.4M |
| Total Liabilities | N/A | N/A | 735K | 1.1M | 1.1M |
| Intangibles | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | N/A | -3.1M | -5.4M | -6.7M | -6.7M |
| Working Capital | -1.4M | 1.6M | N/A | N/A | N/A |
| Current Assets | 236K | 3.0M | 867K | 464K | 464K |
| Current Liabilities | 1.7M | 1.4M | N/A | N/A | N/A |
| Per Share Data | |||||
| EPS | N/A | N/A | N/A | N/A | 0.00 |
| Owner EPS | N/A | N/A | N/A | N/A | N/A |
| Book Value | N/A | N/A | N/A | N/A | 0.00 |
| Cash Flow/Share | N/A | N/A | N/A | N/A | 0.00 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | N/A | N/A | N/A | N/A | 0.0M |
| Valuation | |||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A |
| P/FCF | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A | N/A | N/A |
| Market Cap | 0 | 0 | 0 | 0 | 0 |
| Avg. Price | 13.02 | 10.52 | 8.75 | 6.31 | 8.50 |
| Year-End Price | 16.87 | 8.32 | 9.24 | 5.08 | 8.50 |
ROQUEFORT THERAPEUTICS PLC ORD passes 0 of 9 quality checks, indicating weak fundamentals.
ROQUEFORT THERAPEUTICS PLC ORD (ROQ-L) has a 5-year average return on invested capital (ROIC) of -26.5%. This is below average and may indicate limited pricing power.
ROQUEFORT THERAPEUTICS PLC ORD (ROQ-L) does not currently pay a regular dividend.
ROQUEFORT THERAPEUTICS PLC ORD (ROQ-L) operates in the Biotechnology industry, within the Healthcare sector.
ROQUEFORT THERAPEUTICS PLC ORD (ROQ-L) generated $-1 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ROQUEFORT THERAPEUTICS PLC ORD (ROQ-L) has a return on equity (ROE) of -19.0%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 4 years of financial data for ROQUEFORT THERAPEUTICS PLC ORD (ROQ-L), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
No recent press releases.